C 8 H 12 N 3 O4F, monoclinic, P21/c (no. 14), a = 4.8090(3) Å, b = 9.9340(6) Å, c = 22.2437(13) Å, β = 90.138(8)°, V = 1062.64(11) Å 3 , Z = 4, Rgt(F) = 0.0452, wR ref (F 2 ) = 0.1227, T = 293(2) K.
filtered, slow evaporation afforded colorless needle crystals of the title compound as an unexpected result.
Experimental details
All hydrogen atoms were positioned geometrically and allowed to ride on their parent atoms.
Comment
Pharmaceutical cocrystal compounds [5] have been extensively studied in their structures and pharmacological activity. The stability of some drug molecules will be improved after forming cocrystals with other biocompatible molecules. That's very important for drug industry. 5-Fluorouracil (5-FU) and its derivatives as the first and the most important organic anticancer drugs have been widely investigated over sixty years [6] . Although our original intention is to combine some bioactive groups like 5-FU with coinage metal complexes [7] [8] [9] [10] , we fail to get the target silver complex. Only salt title compound has been obtained and is reported here. The dimethylammonium part of the title compound deduces from the decomposition of DMF [11] .
The title compound has four anions and four cations in the unit cell. The bond lengths and angles are in the normal ranges [4] . Similar to bis(4-dimethylamino-pyridin-1ium) tetrafluorosuccinate [12] , the 5-fluorouracil-1-acetate and dimethylammonium form strong N-H· · · O hydrogen bonds. The adjacent 5-FU groups are forming 5-FU and 5-FU mismatch basepairs via N-H· · · O duplicate hydrogen bonds. This observation is rarely reported in the crystal structures of 5-FU derivatives.
